These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33129994)

  • 1. Reviving an R&D pipeline: a step change in the Phase II success rate.
    Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
    Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
    Schuhmacher A; Wilisch L; Kuss M; Kandelbauer A; Hinder M; Gassmann O
    Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 5. R&D productivity rides again?
    Lendrem D; Senn SJ; Lendrem BC; Isaacs JD
    Pharm Stat; 2015; 14(1):1-3. PubMed ID: 25336017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity.
    Fernando K; Menon S; Jansen K; Naik P; Nucci G; Roberts J; Wu SS; Dolsten M
    Drug Discov Today; 2022 Mar; 27(3):697-704. PubMed ID: 34922020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escaping the pincer.
    Nat Rev Drug Discov; 2009 Dec; 8(12):915. PubMed ID: 19967796
    [No Abstract]   [Full Text] [Related]  

  • 9. The case for entrepreneurship in R&D in the pharmaceutical industry.
    Douglas FL; Narayanan VK; Mitchell L; Litan RE
    Nat Rev Drug Discov; 2010 Sep; 9(9):683-9. PubMed ID: 20725093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
    Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
    Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Description of the French players from Avenir's investment program: the role of MabDesign].
    Groux N; Pontremoli R; Vuddamalay G; Richard G; Pons D
    Med Sci (Paris); 2019 Dec; 35(12):1198-1201. PubMed ID: 31903939
    [No Abstract]   [Full Text] [Related]  

  • 12. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
    Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
    Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concerns raised over declining antiinfectives R&D.
    Fox JL
    Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical R&D: the road to positive returns.
    David E; Tramontin T; Zemmel R
    Nat Rev Drug Discov; 2009 Aug; 8(8):609-10. PubMed ID: 19644471
    [No Abstract]   [Full Text] [Related]  

  • 15. Can quantitative pharmacology improve productivity in pharmaceutical research and development?
    Patel M; Bueters T
    Expert Opin Drug Discov; 2020 Oct; 15(10):1111-1114. PubMed ID: 32511018
    [No Abstract]   [Full Text] [Related]  

  • 16. A decade of innovation in pharmaceutical R&D: the Chorus model.
    Owens PK; Raddad E; Miller JW; Stille JR; Olovich KG; Smith NV; Jones RS; Scherer JC
    Nat Rev Drug Discov; 2015 Jan; 14(1):17-28. PubMed ID: 25503514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The productivity crisis in pharmaceutical R&D.
    Pammolli F; Magazzini L; Riccaboni M
    Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does size matter in R&D productivity? If not, what does?
    Ringel M; Tollman P; Hersch G; Schulze U
    Nat Rev Drug Discov; 2013 Dec; 12(12):901-2. PubMed ID: 24136396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.